Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hope this opens at $5/per shares tomorrow.
Link to all SEC filings: https://www.sec.gov/edgar/browse/?CIK=1726711&owner=exclude
8-K filing today…
Item 1.01 Entry into a Material Definitive Agreement.
On November 24, 2021, Aditxt, Inc. (the “Company”) entered into a Warrant Reduction and Release Agreement (the “Warrant Reduction Agreement”) with certain investors (the “Investors”) that are the holders of warrants (the “Warrants”) issued in connection with the Securities Purchase Agreement dated as of August 25, 2021 by and between the Company and each of the Investors (the “Purchase Agreement”). Pursuant to the Warrant Reduction Agreement, the Company agreed to reduce the exercise price of the Warrants to $1.50 per share and to provide the Investors with a right to participate in certain future financings of the Company in consideration of the parties agreeing to certain mutual releases.
The foregoing description of the form of Warrant Reduction Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Warrant Reduction Agreement, a copy of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
Full filing: https://www.sec.gov/ix?doc=/Archives/edgar/data/1726711/000121390021061795/ea151351-8k_aditxtinc.htm
The Largest Law Enforcement Agency in the State of Kansas, Johnson County Sherriff’s Office, to Become First in the Nation to Deploy AditxtScore™ for Immune Scoring for its Employees and First Responders
November 22 2021 - 09:00AM
Business Wire
AditxtScore™ will be used for Assessing Immune Status for COVID-19
Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company that improves the health of the immune system, announced today that the Johnson County Sherriff’s Office, the largest law enforcement agency in the State of Kansas with over 700 employees, will become the first agency in the Nation to deploy AditxtScore™ for assessing the immune status for COVID-19 in its employees.
AditxtScore™ is an immune monitoring platform which provides a personalized and comprehensive profile of the immune system. AditxtScore™ for COVID-19 helps to answer the growing need for a personalized approach to combating the pandemic. AditxtScore™ further differentiates itself by quantitatively measuring the strength of an individual’s immune response to the novel coronavirus with high precision, helping patients and their providers make informed decisions for a proper course of action.
Sheriff Calvin Hayden commented, “If an individual’s antibodies are low, they may decide to get the vaccine or a booster. Alternatively, if their antibodies are high, either due to natural infection or from the vaccine, it may be best for them to wait on the booster. With their AditxtScore™, they will finally have the information to guide these important health decisions – information they do not currently have. Informed individuals are empowered to make healthy decisions.” He added, “The Johnson County Sheriff's Office has done a stellar job of managing COVID-19. We haven’t skipped a beat in the services we’ve provided, and the AditxtScore™ immune profile takes it to the next level.”
“AditxtScore™ provides meaningful information to help understand one’s personal immune response to COVID-19 and not just that of the population collectively,” said Amro Albanna, Co-founder and Chief Executive Officer of Aditxt. Aditxt’s immune monitoring platform is a pioneering approach to the health of our immune system. “Precision immunotherapies can only be effectively developed when we have a better understanding of the immune system. This understanding is the guiding principle of AditxtScore™,” Amro added. “AditxtScore™ for COVID-19 application provides an opportunity to assess the immunity status in response to COVID-19 by measuring levels of multiple antibody isotypes (IgM, IgG and IgA) that can develop against components of the spike protein encoded by current vaccines, as well as additional viral proteins that can be produce in response to natural infection. Additionally, measurement of the neutralizing capabilities of these antibodies further illustrates the effectiveness of the immune response to help protect against future infections.”
Dave Owen, President of KanVest Services, an Aditxt channel partner and advisor to the Johnson County Sherriff’s Office, commented, “AditxtScore™ provides a unique, precise, and comprehensive test that delivers so much more than simply a ‘negative’ or ‘positive’ test result, as with standard antibody tests. Just as not all people are alike in how their bodies respond to the virus and/or the vaccine, not all antibody tests are alike. How are individuals to know if they have a ‘high protective level of antibodies’ or ‘low at-risk level of antibodies’ or ‘no antibodies’ given the fact that most tests on the market simply indicate ‘yes, you have some antibodies’, or ‘no, you do not have antibodies’. We are proud to be a channel partner of Aditxt and distribute the AditxtScore™ for COVID-19. It equips individuals with their personal immune profile so they can make informed decisions about their health. The AditxtScore™ immune monitoring tool is an essential component for the public and private sectors, managing through the COVID-19 pandemic.”
About Aditxt™
Aditxt develops technologies focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt’s immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt’s immune reprogramming technology, currently in the preclinical state, is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. AditxtScore™ for COVID-19 is Aditxt’s proprietary immune profile technology to equip people with information about their personal level of protection. For more information, please visit: www.aditxt.com www.AditxtScore™.com
About KanVest Services
KanVest Services is a healthtech company that provides products and services that support preventive health, for the public and private sectors across the US. KanVest is a national distributor of AditxtScore™ for COVID-19, a comprehensive immune profile that measures the strength of an individual’s immune response to COVID-19, so they can make informed decisions with the optimal course of action for their health, to better navigate the global pandemic. …getting America back to normal with confidence– using science. www.Kanvest.com
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006231/en/
Media and Investor Relations Contact:
Aditxt, Inc.
ir@aditxt.com
Isn't this the company that ADTX IS TENTATIVELY BUYING THE ASSETS that has been halted today from trading pending news:
11/11/2021 11:53:44
APLIF
APPILI THERAPEUTICS INC CL A (Canada)
U1
Other OTC
Halt
link:
https://otce.finra.org/otce/tradingHalts
AiPharma Global generates revenues from worldwide sales outside the U.S. and Canada of Avigan/Reeqonus through its 50% equity stake in Global Response Aid ("GRA"). GRA is part of a consortium that includes Appili Therapeutics (TSX: APLI[/b]; OTCQX: APLIF), Dr. Reddy’s Laboratories (NYSE:RDY), Agility (KSE/DFM: AGLTY) and FUJIFILM Toyama Chemical Co. Ltd, a subsidiary of FUJIFILM Holdings (FUJIY). The consortium members work together to coordinate and accelerate the worldwide development of Avigan/Reeqonus.
Rock and roll I added another chunk of shares to ADTX this morning. This one will be a huge winner as long as all things come into place. $$$$. The penny king cant afford this one so watch and ADTX run big.$$$$$
Well aware of that PR released by ADTX.
Also, willing to bet the anticipated closing on 11/30 is contingent on excellent reults from phase 3. That's why the date of the closing was set for 11/30.
"The acquisition is subject to confirmatory due diligence, entry into a definitive agreement based on agreed terms and other closing conditions, including regulatory, board, shareholder, and Nasdaq approvals. There is no assurance that the aforementioned approvals will be granted."
Pending merge/acquisition as well expected reach a definitive agreement by the end of this month.
"Agreement to reach a definitive agreement by the end of November 2021 to acquire a subsidiary ("AiPharma") of AiPharma Global Holdings LLC ("AiPharma Global") which is to own all of the assets of AiPharma Global, a company focused on discovering, developing and commercializing antiviral therapies across a broad spectrum of infectious diseases.
https://finance.yahoo.com/news/aditxt-signs-transaction-agreement-acquire-124500511.html
Pending merge/acquisition also phase3 data trials expected to be announced by 20-22 next week.
"Agreement to reach a definitive agreement by the end of November 2021 to acquire a subsidiary ("AiPharma") of AiPharma Global Holdings LLC ("AiPharma Global") which is to own all of the assets of AiPharma Global, a company focused on discovering, developing and commercializing antiviral therapies across a broad spectrum of infectious diseases.
https://finance.yahoo.com/news/aditxt-signs-transaction-agreement-acquire-124500511.html
Fully loaded!
LINK:
https://www.wsj.com/articles/aipharma-signs-binding-agreement-to-sell-to-aditxt-inc-nasdaq-adtx-aipharma-is-the-rights-holder-of-antiviral-tablet-avigan-reeqonus-qifenda-that-has-treated-over-1-5m-covid-19-patients-since-the-outbreak-01633452430?tesla=y
From the 10/5/2021 PR:
" Consortium partner Appili Therapeutics is running a global Phase 3 trial evaluating Avigan/Reeqonus as an oral at-home therapy for COVID-19 and recently announced completion of patient enrollment with top line data expected within 45 days. Appili has also planned a Phase 3 post-exposure prophylaxis study designed to evaluate Avigan/Reeqonus for the prevention of COVID-19 when given to asymptomatic individuals who have had direct exposure to an infected person. Appili expects to initiate following successful completion of the treatment study. "
That would be appox. 19th this month
Not as many many posts as I expected …
Watching this one .
$ADTX
Great question - would love to know
Aditx therA
What is the catalyst here?
Waiting game phase3 data expected on 19-22 this month
I now own 98000 shares at great prices and I am looking for higher prices with the next piece of news to come out. have a great day and lets see what happens next with the covid pills
Nice bounce today and looking for much higher price with having a COVID pill that works
own 78000 shares now and Ill see you at much higher prices. Read the news and do the dd this is a easy buy under 1.85. MRK was approved in the UK and our product is needed along with theirs.
Right here is the perfect Fibonacci retracement level from the explosive move up we just had and yes Im a buyer of ADTX
been a buyer of the shares today that I sold last week above 2.50. A gift is a gift...........
Merck's pill has been approved in Britain and the stock is down 9%.
So adtx decline from a big run up should not be a concern.
Overbought chart
Reason for move yesterday:
Merck had malnupiravir approved in the UK. According to the study below, it’s efficacy is substantially improved when combined with favipiravir (Avigan) which ADXT is about to acquire with merger.
"with a combination of favipiravir and molnupiravir suggest that the combination has significantly greater antiviral activity than either drug alone with SARS-CoV-2."
Binding agreement was announced on 10/5/2021 for favipiravir (Avigan.
AiPharma Signs Binding Agreement To Sell To Aditxt Inc (Nasdaq: ADTX). AiPharma Is The Rights Holder Of Antiviral Tablet Avigan / Reeqonus / Qifenda That Has Treated Over 1.5M COVID-19 Patients Since The Outbreak.
lol now a couple of hedge funds know about ADTX watch it run.............
Great day for ADTX
Run ADTX run ...... I have a huge position here and today is the start of making a huge profit. Nobody knows yet that ADTX is a Player in the Covid Pill market. Let them soon find out lol.
Well todays news on MRK and the covid pill will help us here at ADTX. With the placement completed many shares are now in the right hands to move ADTX higher.
Phase 3 data IMMINENT this one going to explodeeeee on positive data
Too bad this is another scam stock... Man when will these scammers stop stealing from the public???? the deal is so under water no body makes money but the ones that do the deal 1.76 today Oct 11th they shorted the deal with the warrants imo
Aditxt Inc. shares were down 30% to $2.14 after the company said it has entered into agreements with certain (LOL) institutional investors to buy 4.6 million common shares at $2.40 a share in a registered direct offering.
The biotechnology company said it expects to see proceeds of $11 million , before payment of commissions and expenses.
In a concurrent private placement, for each share bought by an investor, that investor will receive an unregistered warrant to purchase one share. The warrants have an exercise price of $2.53 a share, and are exercisable for a five-year period beginning six months from the date of issuance.
Aditxt said it plans to use the proceeds from this offering to fund a $6.5 million loan to a biopharmaceutical company commercializing Covid-19 antiviral oral therapy, and for general corporate and working capital purposes, including the purchase of fixed assets.
Covid Pill Phase 3 data within 4 weeks ,,market cap only $33m there could be a very nice jump on positive outcome
AiPharma Signs Binding Agreement To Sell To Aditxt Inc (Nasdaq: ADTX). AiPharma Is The Rights Holder Of Antiviral Tablet Avigan / Reeqonus / Qifenda That Has Treated Over 1.5M COVID-19 Patients Since The Outbreak.
https://finance.yahoo.com/news/aipharma-signs-binding-agreement-sell-164100791.html
Phase 3 clinical trial of Avigan/Reeqonus for treatment of COVID-19 completed enrollment of more than 1,200 patients in the U.S., Mexico and Brazil with topline results expected within 45 days
out even
Coincidence???
Lauren Chung is on the Board of Todos and the Board of Aditxt- see links below:
Todos -- 4/2020
https://www.nasdaq.com/press-release/todos-medical-appoints-dr.-lauren-chung-to-its-board-of-directors-2020-04-17
ADTX--- 6/18/21
https://www.financialbuzz.com/aditxt-announces-the-appointment-of-dr-lauren-chung-to-its-board-of-directors/
Company Prepares for Global Commercialization?
After hours closed price is $1.83
Possibly a good sign for Monday morning news for the previously announced LOI for an acquisition that they reached a definitive agreement .
Just have to wait and see.
ADTX teusday was a "hug" but thursday I feel more like a "squeeezzzze".
Aditxt is advancing its negotiations and due diligence under an exclusive LOI to reach a definitive agreement to acquire a biopharmaceutical company that is commercializing a COVID-19 antiviral oral therapy by September 30, 2021.
Could this be the takeover candidate for ADTX------Todos Medical ltd?
Phase 2 Drug Candidate for COVID-19 Todos is developing a more concentrated version of Tollovid for COVID-19 infected patients, using a proprietary blend of botanical extracts with an active chemical ingredient that limits replication of coronaviruses. Todos is currently supporting randomized, placebo-controlled clinical trials managed by JV partner NLC Pharma in Israel. Tollovir is the result of over 15 years of development and an investment of over $18M to date.
https://investor.todosmedical.com/news-events/press-releases/detail/132/todos-medical-receives-trademark-notice-of-allowance-from
Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Oral Antiviral Drug Candidate Tollovir™
Took an initial position on Friday @ $1.74.
To me ADTX outlook is outstanding! JMO. Especially at the current trading price.
They have a strong balance sheet, very low Shares outstanding ( including new offering), excellent cash on hand, and I believe in a field that will be very big in the future.
Management seems to be upfront and the company is progressing in the right direction.
Only about a year since their IPO.
And there you have it. In case anyone thought it was any safer to hold Nasdaq positions overnight over OTC stocks. Got SCREWED real good with this one today.
I pray it goes up. I’m bag holding lol
Profit taking at the close. Any ideas where the price is going tomorrow???
Followers
|
25
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
477
|
Created
|
08/06/20
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |